Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies
Table 1
Background of the patients based on PP analysis.
RAL group† ( = 24)
RA group‡ ( = 24)
value
Age (mean ± S.D.)
57.8 ± 12.6
61.8 ± 12.6
n.s.∗
Sex (male/female)
10/14
8/16
n.s.∗∗
BMI (mean ± S.D.)
23.0 ± 3.7
21.5 ± 3.4
n.s.∗
Disease, (%)
Gastric ulcer
5 (20.8)
5 (20.8)
n.s.∗∗
Duodenal ulcer
3 (12.5)
5 (20.8)
n.s.∗∗
Early gastric cancer
4 (16.7)
3 (12.5)
n.s.∗∗
Hyperplastic polyp
2 (8.3)
0 (0)
n.s.∗∗
Others
10 (41.7)
11 (45.8)
n.s.∗∗
Success of H. pylori culture (yes/no)a
17/7
11/12
n.s.∗∗
Drug resistance, (%)
Amoxicillin
0 (0)
0 (0)
n.s.∗∗
Clarithromycin
15 (88.2)
8 (72.7)
n.s.∗∗
Metronidazole
13 (76.5)
9 (81.8)
n.s.∗∗
Levofloxacin
6 (35.3)
7 (63.6)
n.s.∗∗
CYP2C19 polymorphism (EM/PM)b
20/2
13/9
<0.05∗∗
RAL group: RPZ 10 mg (b.i.d.), AMPC 750 mg (b.i.d.), and LVFX 500 mg (o.d.). ‡RA group: RPZ 10 mg (q.i.d.) and AMPC 500 mg (q.i.d.). BMI, body mass index; EM, extensive metabolizer; PM, poor metabolizer; aone patient in RA group refused the drug sensitivity test; bfour patients (two in RAL group and two in RA group) refused the analysis of CYP2C19 polymorphism; ∗unpaired -test; ∗∗chi-square test.
